IOL
Chemicals and Pharmaceuticals Ltd
Q2 FY 20 RESULTS
- REVIEW
About IOL Chemicals and
Pharmaceuticals Limited (IOLCP)
Company was established in
1986 is one of the leading Active Pharmaceutical ingredients/ bulk drugs manufacturing
Company and is a significant player in the specialty chemicals space with world
class facilities.
IOLCP has wide presence across major therapeutic categories like,
Pain Management, anti-convulsants, anti-diabetes, anti- cholesterol and
anti-platelets.
IOLCP's product
portfolio includes Active Pharmaceutical lngredients; Ibuprofen,
Metformin, Fenofibrate,
Clopidogrel, Lamotrigine, Pantoprazole
and specialty chemicals
such as Ethyl Acetate, lso Butyl Benzene, Mono Chiaro Acetic Acid
and Acetyl Chloride.
Company is World's largest
producer of the Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility.
The Company has DSIR
approved R&D which is fully equipped to validate existing processes.
The Central and
State Government approved Effluent Treatment Plant (ETP) had been
set up with zero
effluent discharge system along with
17 MW captive
Co- Generation plant for self reliance.
IOLCP's overseas customers
are spread out across several countries
including UK, Austria, Belgium,
Hungry, Spain, Germany, Italy, Netherlands, Switzerland, Portugal, Poland, Ireland,
USA, Australia, Chile,
Peru, Brazil, Argentina,
Colombia, Mexico, Indonesia, South
Korea, Thailand etc.
Products are
sold primarily to
Branded Generic formulators both in India & Overseas
IOL has posted remarkable
operational and financial performance for the second quarter of financial year
2019-20. It was after a consistent first quarter performance.
Quarter ended September 2019
vis a vis Quarter ended September 2018
• Income from operations
increased by 5 % to~Rs.452 crore from Rs.429 crore.
• EBIDTA increased by 68 %
to~Rs.136 crore from Rs.81 crore.
• Net Profit increased by
132 % to~Rs.88 crore from Rs.38 crore.
• EPS increased by 125 % to Rs.15.42
from Rs.6.84.
Half year ended September
2019 vis a vis Half year ended September 2018
• Income from operations
increased by 19 % to~ 948 crore from Rs.794 crore.
• EBIDTA increased by 129 %
to Rs.284 crore from Rs.124 crore.
• Net Profit increased by
226 % to Rs.173 crore from Rs.53 crore.
• EPS increased by 224 % to
Rs.30.42 from Rs.9.40.
Mr Vijay Garg, Joint
Managing Director said :
"We are very delighted
to announce consistently strong operational and financial performance during
the 2ndquarter of the Financial Year 2019-20.
We have successfully set up
Unit VI to manufacture Pantoprazole with a capacity of 240 MT per annum which
will enable to increase the revenue of the Company.
He further added, we have
made the pre-payment of term loan of aggregate amount of Rs.161.44 crore till
date to reduce the financial cost of the Company."
